CJC-1295 and Ipamorelin: In-Vitro Receptor Research
CJC-1295 (no DAC) and Ipamorelin: their distinct GH-secretagogue receptor pathways, and why the two peptides are studied together in vitro.
Growth hormone (GH) secretion from pituitary somatotroph cells is regulated by two principal hypothalamic inputs operating through distinct receptor systems: growth hormone-releasing hormone (GHRH), which acts via the GHRH receptor (GHRHR), and the ghrelin/GHS-R axis, mediated through the growth hormone secretagogue receptor 1a (GHS-R1a). CJC-1295 (no DAC) and Ipamorelin are synthetic research peptides studied in vitro as selective ligands for these two complementary receptor pathways. Understanding their individual pharmacological profiles and the mechanistic rationale for their combined use in research models requires a detailed account of both the receptor biology and the structural chemistry of each compound.
The GHRH receptor pathway and CJC-1295 (no DAC)
The endogenous GHRH peptide is a 44-amino-acid hypothalamic neuropeptide that binds GHRHR, a class B1 G protein-coupled receptor (GPCR) coupled primarily to Gs. GHRHR activation stimulates adenylyl cyclase, elevating intracellular cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA), which phosphorylates transcription factors including CREB to drive GH gene expression and secretagogue release. The N-terminal 29 residues of GHRH (GRF(1-29)) retain full biological activity at GHRHR. CJC-1295 no-DAC — also referred to as Modified GRF(1-29) — is a 29-amino-acid analogue of GRF(1-29) in which four residue substitutions confer resistance to dipeptidyl peptidase IV (DPP-IV) cleavage: Ala2→D-Ala, Gln8→Ala, Ala15→Ala (already native, retained), and Leu27→Arg. These substitutions extend the plasma half-life of the peptide in research models relative to native GRF(1-29) while maintaining GHRHR binding affinity.
The ghrelin/GHS-R1a pathway and Ipamorelin
The growth hormone secretagogue receptor 1a (GHS-R1a) is a GPCR coupled to Gq/11 as well as Gs, and its activation by the endogenous ligand ghrelin (or by synthetic GHS-R1a agonists) stimulates phospholipase C-mediated IP3/DAG signalling in addition to cAMP elevation. This dual second-messenger engagement is mechanistically distinct from the exclusively Gs-coupled GHRHR pathway. Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH2) is a pentapeptide ghrelin mimetic developed as a selective GHS-R1a agonist. Its primary pharmacological distinction in receptor-selectivity studies is that it activates GHS-R1a without the adrenocorticotropic hormone (ACTH)/cortisol or prolactin release observed with earlier generation GHS-R1a agonists such as GHRP-2 and GHRP-6. Radioligand binding assays and ex-vivo pituitary cell studies have attributed this selectivity to Ipamorelin's pentapeptide structure, which lacks the off-target agonist activity at corticotroph GHRP binding sites that characterises the hexapeptide GHRPs.
cAMP signalling and somatotroph cell models
In primary rat anterior pituitary cell cultures and GH3 somatotroph cell line models, GHRHR and GHS-R1a activation individually produce submaximal cAMP elevation and GH secretion relative to maximal stimulus. The mechanistic basis for their synergistic interaction in dual-stimulation experiments relates to convergence on adenylyl cyclase from two distinct GPCR inputs: GHRHR-coupled Gs activates adenylyl cyclase directly, while GHS-R1a-coupled Gq/11 generates diacylglycerol (DAG), activating protein kinase C (PKC), which further potentiates adenylyl cyclase activity. The net result in in-vitro somatotroph assays is a cAMP accumulation and GH secretion response that exceeds the sum of either stimulus applied individually — the classical definition of pharmacological synergy, quantifiable by Bliss independence or Loewe additivity analysis.
Combination rationale in in-vitro assay design
- Receptor pathway complementarity: GHRHR (Gs/cAMP) and GHS-R1a (Gq/PKC/cAMP) engage distinct intracellular signalling arms, providing mechanistically orthogonal stimulation of somatotroph secretion
- Selectivity profiling: Ipamorelin's GHS-R1a selectivity allows researchers to isolate GHS-R1a-dependent signalling from ACTH/cortisol confounds, which is not possible with GHRP-2 or GHRP-6 in mixed-cell pituitary preparations
- DPP-IV resistance: Modified GRF(1-29) substitutions allow extended incubation periods in cell culture media containing serum DPP-IV activity without rapid N-terminal cleavage of the test compound
- Synergy quantification: the combination is used in in-vitro models to characterise the GH secretory response surface and to establish concentration-response relationships for cAMP and downstream PKA/CREB phosphorylation
- All applications described are in-vitro laboratory research protocols conducted for investigative purposes only
Research-grade compound requirements
The mechanistic precision of GHS-R1a and GHRHR pharmacology research depends on compounds of verified sequence and purity. Modified GRF(1-29) in particular is susceptible to truncation at the N-terminus during synthesis; truncated sequences (e.g. GRF(3-29)) have measurably reduced GHRHR binding affinity and would confound concentration-response analysis. Vivera Labs supplies both CJC-1295 (no DAC) and Ipamorelin as independently tested, batch-specific lyophilised powders with HPLC purity and MS identity confirmation from a US-based third-party laboratory. All materials are supplied for in-vitro laboratory research use only.
Frequently Asked Questions
What are CJC-1295 (no DAC) and Ipamorelin?
CJC-1295 (no DAC) and Ipamorelin are synthetic research peptides studied in vitro as selective ligands for two complementary receptor pathways involved in growth hormone regulation. CJC-1295 no-DAC, also called Modified GRF(1-29), is a 29-amino-acid analogue of GRF(1-29) that binds the GHRH receptor, while Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH2) is a pentapeptide ghrelin mimetic studied as a selective GHS-R1a agonist. Both are supplied for in-vitro laboratory research use only.
Why are CJC-1295 and Ipamorelin studied together in research?
In in-vitro somatotroph assays, the GHRHR pathway (Gs/cAMP) and the GHS-R1a pathway (Gq/PKC/cAMP) engage distinct intracellular signalling arms, providing mechanistically orthogonal stimulation. The combination is used to characterise the growth-hormone secretory response surface and to establish concentration-response relationships for cAMP and downstream PKA/CREB phosphorylation. All applications described are in-vitro laboratory research protocols conducted for investigative purposes only.
What makes Ipamorelin selective in receptor studies?
In radioligand binding assays and ex-vivo pituitary cell studies, Ipamorelin activates GHS-R1a without the ACTH/cortisol or prolactin release observed with earlier-generation agonists such as GHRP-2 and GHRP-6. This selectivity has been attributed to its pentapeptide structure, which lacks the off-target agonist activity at corticotroph binding sites that characterises the hexapeptide GHRPs. This allows researchers to isolate GHS-R1a-dependent signalling from ACTH/cortisol confounds.
What does the DPP-IV resistance of Modified GRF(1-29) mean for research?
CJC-1295 no-DAC carries four residue substitutions that confer resistance to dipeptidyl peptidase IV (DPP-IV) cleavage, extending the peptide’s stability in research models while maintaining GHRHR binding affinity. In practice, this allows extended incubation periods in cell culture media containing serum DPP-IV activity without rapid N-terminal cleavage of the test compound. Verified sequence and purity matter because truncated sequences such as GRF(3-29) have measurably reduced GHRHR binding affinity.
For in-vitro laboratory research use only. Not for human or veterinary use, consumption, or therapeutic application. No medical claims are made.